Drug intelligence / Profile preview

HB-301

Development stage: Discontinued
Lead developer: HOOKIPA Pharma
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

HB-301 is a therapeutic cancer vaccine developed by Hookipa Pharma for the treatment of prostate cancer, specifically metastatic castration-resistant prostate cancer. It is designed as an immunotherapy that stimulates the immune system to target and attack prostate cancer cells. The mechanism of action involves immunostimulation, with specific inhibition of acid phosphatase 3 (ACP3), prostate-specific antigen (KLK3), and prostate-specific membrane antigen (PSMA). Clinical development reached phase I/II trials in metastatic prostate cancer, but these trials were terminated for non-safety related reasons.

Other names: HB 301HB301HB-301

Targets

PSA (Puromycin-sensitive aminopeptidase)PAP (Prostatic acid phosphatase)

Beyond the preview

Go deeper on HB-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HB-301.

Explore the full profile